MCID: ANG015
MIFTS: 56

Angioedema

Categories: Bone diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Oral diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Angioedema

MalaCards integrated aliases for Angioedema:

Name: Angioedema 12 74 54 6 44 15 17 71
Angioneurotic Oedema 12 32
Quincke's Edema 12 74
Angioneurotic Edema 12
Giant Urticaria 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1558
MeSH 44 D000799
NCIt 50 C112175
SNOMED-CT 67 41291007
ICD10 32 T78.3
UMLS 71 C0002994

Summaries for Angioedema

Disease Ontology : 12 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary : Angioedema, also known as angioneurotic oedema, is related to angioedema, hereditary, type i and acquired angioedema, and has symptoms including edema and peau d'orange. An important gene associated with Angioedema is F12 (Coagulation Factor XII), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Omalizumab and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Angioedema is an area of swelling (edema) of the lower layer of skin and tissue just under the skin or... more...

Related Diseases for Angioedema

Diseases in the Angioedema family:

Angioedema, Hereditary, Type I Angioedema, Hereditary, Type Iii
Hereditary Angioedema Acquired Angioedema
Acquired Angioedema Type 1 Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 591)
# Related Disease Score Top Affiliating Genes
1 angioedema, hereditary, type i 33.0 SERPING1 PLG F12
2 acquired angioedema 32.9 SERPING1 C1S
3 c1 inhibitor deficiency 32.0 SERPING1 KNG1 KLKB1 F12 C1S BDKRB2
4 hereditary angioedema 31.1 XPNPEP2 SERPING1 PLG PLAT KNG1 KLKB1
5 chronic urticaria 30.9 PTGS1 HRH1 HNMT CPN1 ACE
6 hereditary angioedema with normal c1inh 30.8 PLG PLAT KNG1 DPP4 CPN1 C1S
7 physical urticaria 30.8 SERPING1 KNG1 HRH1
8 cholinergic urticaria 30.7 SERPING1 HRH1
9 allergic urticaria 30.5 SERPING1 KNG1
10 hydrops, lactic acidosis, and sideroblastic anemia 30.4 SERPING1 PTGS2 PTGS1 KNG1 C1S
11 urticaria 30.3 SERPING1 PTGS2 PTGS1 LTC4S IL5 HRH1
12 rhinitis 30.0 PTGS1 KNG1 IL5 HRH1
13 conjunctivitis 29.8 PLG IL5 HRH1
14 stroke, ischemic 29.7 PLG PLAT ANGPT1 ACE
15 migraine with or without aura 1 29.7 PTGS2 PLG KNG1 ACE
16 proteasome-associated autoinflammatory syndrome 1 29.6 PTGS2 PTGS1 IL5
17 ischemia 29.5 PLG PLAT KNG1 ANGPT1 ACE
18 vascular disease 28.9 PTGS2 PTGS1 PLG PLAT KNG1 ANGPT1
19 asthma 28.5 PTGS1 MME LTC4S KNG1 IL5 HRH1
20 cardiovascular system disease 28.4 PTGS2 PTGS1 PLG PLAT MME KNG1
21 hypertension, essential 27.5 PTGS2 PTGS1 PLG PLAT MME KNG1
22 angioedema, hereditary, type iii 11.7
23 angioedema induced by ace inhibitors 11.7
24 vibratory urticaria 11.5
25 episodic angioedema with eosinophilia 11.4
26 non-histaminic angioedema 11.1
27 carboxypeptidase n deficiency 11.1
28 cold urticaria 10.9
29 hereditary angioedema with c1inh deficiency 10.9
30 acquired angioedema type 1 10.9
31 acquired angioedema type 2 10.9
32 complement component 4, partial deficiency of 10.9
33 loiasis 10.9
34 plg-related hereditary angioedema with normal c1inh 10.9
35 angpt1-related hereditary angioedema with normal c1inh 10.9
36 acquired angioedema with c1inh deficiency 10.9
37 netherton syndrome 10.9
38 hypereosinophilic syndrome 10.6
39 exanthem 10.5
40 chronic spontaneous urticaria 10.4
41 louse-borne relapsing fever 10.4 SERPING1 C1S
42 allergic disease 10.4
43 pseudomembranous conjunctivitis 10.4 SERPING1 PLG
44 acute anterolateral myocardial infarction 10.4 PLG ACE
45 lateral myocardial infarction 10.4 PLG ACE
46 anteroseptal myocardial infarction 10.4 PLG ACE
47 alveolar periostitis 10.4 PLG KNG1
48 melkersson-rosenthal syndrome 10.4 SERPING1 ACE
49 cholesterol embolism 10.4 PLG ACE
50 intracranial vasospasm 10.3 KNG1 ACE

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to Angioedema

Symptoms & Phenotypes for Angioedema

UMLS symptoms related to Angioedema:


edema, peau d'orange

GenomeRNAi Phenotypes related to Angioedema according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.55 ANGPT1 BDKRB2 F12 HRH1 IL5 KLKB1
2 Decreased viability GR00381-A-1 9.55 BDKRB2 F12 HNMT KLKB1 PLAT
3 Decreased viability GR00381-A-3 9.55 BDKRB2
4 Decreased viability GR00386-A-1 9.55 ANGPT1 HNMT
5 Decreased viability GR00402-S-2 9.55 ANGPT1 F12

MGI Mouse Phenotypes related to Angioedema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 ACE BDKRB2 CPN1 HNMT HRH1 IL5
2 cardiovascular system MP:0005385 10.03 ACE ANGPT1 BDKRB2 DPP4 KLKB1 LTC4S
3 homeostasis/metabolism MP:0005376 10 ACE ANGPT1 BDKRB2 DPP4 F12 HRH1
4 immune system MP:0005387 9.77 ACE ANGPT1 BDKRB2 CPN1 DPP4 HRH1
5 respiratory system MP:0005388 9.17 DPP4 IL5 LTC4S PLAT PLG PTGS1

Drugs & Therapeutics for Angioedema

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Lactitol Approved, Investigational Phase 4 585-86-4 157355
3
Icatibant Approved, Investigational Phase 4 130308-48-4, 138614-30-9 71364
4
Bradykinin Investigational Phase 4 58-82-2 439201
5 Respiratory System Agents Phase 4
6 Anti-Asthmatic Agents Phase 4
7 Anti-Allergic Agents Phase 4
8 gamma-Globulins Phase 4
9 Rho(D) Immune Globulin Phase 4
10 Kininogens Phase 4
11 Anti-Inflammatory Agents Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Immunosuppressive Agents Phase 4
14 Angiotensin-Converting Enzyme Inhibitors Phase 4
15 Anti-Inflammatory Agents, Non-Steroidal Phase 4
16 Analgesics Phase 4
17 Antirheumatic Agents Phase 4
18 Bradykinin Receptor Antagonists Phase 4
19
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274
20
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
21
tannic acid Approved Phase 3 1401-55-4
22
Tranexamic Acid Approved Phase 3 1197-18-8 5526
23
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
24
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
25
Levocetirizine Approved Phase 3 130018-77-8 1549000
26
Cortisone Experimental Phase 3 53-06-5 222786
27 Kallikreins Phase 3
28 Passionflower Phase 3
29 Coagulants Phase 3
30 Hemostatics Phase 3
31 Antifibrinolytic Agents Phase 3
32 Hormones Phase 3
33 Neurotransmitter Agents Phase 3
34
Histamine Phosphate Phase 3 51-74-1 65513
35 Histamine Antagonists Phase 3
36 Histamine H1 Antagonists Phase 3
37 Hormone Antagonists Phase 3
38 glucocorticoids Phase 3
39 Antineoplastic Agents, Hormonal Phase 3
40 Histamine H1 Antagonists, Non-Sedating Phase 3
41 Immunoglobulins Phase 3
42 Immunoglobulins, Intravenous Phase 3
43 Antibodies Phase 3
44 Pharmaceutical Solutions Phase 3
45 Antibodies, Monoclonal Phase 3
46 Immunoglobulin G Phase 3
47
Racepinephrine Approved Phase 2 329-65-7 838
48
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
49
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862
50 Adrenergic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Prospective Open-label Uncontrolled Multi-center Post-marketing Study to Assess Inhibitory Antibody Formation in Subjects With Congenital C1-INH Deficiency and Acute Hereditary Angioedema (HAE) Attacks Treated With Berinert® , a C1-esterase Inhibitor Completed NCT01467947 Phase 4
2 Open Label, Multicenter Study to Evaluate Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema (IHA) Completed NCT01457430 Phase 4 Icatibant
3 A Phase 4 Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE® (C1 Inhibitor [Human]) as Prophylactic Therapy in Subjects With Inadequately Controlled Hereditary Angioedema Attacks Completed NCT00914966 Phase 4
4 Hereditary Angioedema : Interest From the Use of a Call Center During the Attacks. Completed NCT01679912 Phase 4
5 A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Xolair (Omalizumab) for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy Completed NCT02966314 Phase 4 Omalizumab;Placebos
6 A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions Recruiting NCT03576469 Phase 4
7 Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema - a Mulitcenter Trial Terminated NCT01574248 Phase 4 icatibant
8 Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Determine the Efficacy of 1000u, and 1500u of C1-INH Compared to Placebo at the Time of Prodromal Symptoms in Preventing an Acute HAE Exacerbation. Withdrawn NCT01151735 Phase 4 C-1-esterase;C-1-esterase;placebo
9 A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema Completed NCT02584959 Phase 3 C1 esterase inhibitor [human] liquid;Placebo
10 A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE) Completed NCT02865720 Phase 3 CINRYZE 500 U;CINRYZE 1000 U
11 A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema Completed NCT02052141 Phase 3
12 A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema Completed NCT01912456 Phase 3
13 An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema Completed NCT02316353 Phase 3
14 Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults Completed NCT01919801 Phase 3 Icatibant;Placebo
15 Pharmacokinetics Berinert P Study of Subcutaneous Versus Intravenous Administration in Subjects With Moderate Hereditary Angioedema - The Passion Study Completed NCT00748202 Phase 3 C1-Esterase Inhibitor
16 HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) Completed NCT02741596 Phase 3 DX-2930;DX-2930
17 LEVP2006-4 CHANGE 3 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Use of C1INH-nf (Human) for the Prophylactic Treatment to Prevent HAE Attacks and as Treatment in Acute HAE Attacks Completed NCT00462709 Phase 3
18 Open-label Patient Continuation of DX-88 (Ecallantide) for Acute Hereditary Angioedema Attacks Completed NCT00456508 Phase 3 ecallantide
19 A Randomized, Placebo-controlled, Double Blind Phase II/III Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00225147 Phase 2, Phase 3 Recombinant Human C1 Inhibitor;placebo
20 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125541 Phase 2, Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
21 Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema Completed NCT00125151 Phase 3 C1 inhibitor concentrate (C1-esteraseremmer-N)
22 Randomized, Double Blind, Placebo-Controlled, Multicenter Study of a Subcutaneous Formulation of Icatibant for the Treatment of Hereditary Angioedema Completed NCT00097695 Phase 3 Icatibant;Placebo
23 Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema Completed NCT01843530 Phase 3 Berinert;Clemastin;Cortisone acetate;NaCl
24 A Phase III Randomized, Double-blind, Placebo-controlled Study With an Open-label Extension Evaluating the Efficacy, Safety and Immunogenicity of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks of Angioedema in Patients With HAE Completed NCT01188564 Phase 3 rhC1INH;Placebo (Saline)
25 EDEMA4: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of DX-88 (Ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema Completed NCT00457015 Phase 3 ecallantide;Phosphate Buffer Saline (PBS), pH 7.0
26 A Randomized, Placebo-controlled, Double-blind Phase III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262301 Phase 3 recombinant human C1 inhibitor;Placebo
27 A Phase II/III Study of the Efficacy and Safety of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Completed NCT00262288 Phase 2, Phase 3 i.v. recombinant human C1 inhibitor
28 A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents With Hereditary Angioedema Completed NCT01386658 Phase 3 icatibant
29 LEVP2006-1 CHANGE 2 Trial (C1-Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy): Open-Label Safety/Efficacy Repeat Exposure Study of C1INH-nf (Human) in the Treatment of Acute HAE Attacks Completed NCT00438815 Phase 3
30 A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema Completed NCT00262080 Phase 3 ecallantide;Phosphate Buffer Saline (PBS),
31 A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy. Completed NCT01723072 Phase 3 Placebo
32 HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE) Completed NCT02586805 Phase 3 DX-2930 - 300mg/2wk;DX-2930 - 300mg/4wk;DX-2930 - 150mg/4wk;Placebo
33 A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE) Completed NCT00912093 Phase 3 Icatibant;Placebo
34 Open Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema Completed NCT00997204 Phase 3 Icatibant
35 An Open-Label Study of Icatibant in Japanese Subjects With Acute Attacks of Hereditary Angioedema. Completed NCT03888755 Phase 3 Icatibant
36 OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema Completed NCT02303626 Phase 2, Phase 3 BCX4161;Placebo
37 Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE) Completed NCT00500656 Phase 3 Icatibant;Tranexamic Acid;Oral Placebo;S.C. Placebo
38 Open-label Extension Study of CE1145 (Human Pasteurized C1 Esterase Inhibitor Concentrate) in Subjects With Congenital C1-INH Deficiency and Acute HAE Attacks Completed NCT00292981 Phase 3 C1 Esterase Inhibitor
39 LEVP2005-1/Part A: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) for the Treatment of HAE in Acute Attacks Completed NCT00289211 Phase 3 Placebo (saline)
40 Human Pasteurized C1 Esterase Inhibitor Concentrate (CE1145) in Subjects With Congenital C1-INH Deficiency and Acute Abdominal or Facial HAE Attacks Completed NCT00168103 Phase 2, Phase 3
41 LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks Completed NCT01005888 Phase 3 Placebo (saline)
42 A Multicenter, Open-Label, Non-randomized Phase 3 Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneous Administration of Icatibant (TAK-667) in Japanese Children and Adolescents With Acute Attacks of Hereditary Angioedema Recruiting NCT04654351 Phase 3 TAK-667
43 A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Recruiting NCT04656418 Phase 3 Placebo
44 A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects With Hereditary Angioedema Recruiting NCT04180163 Phase 3 Lanadelumab
45 A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) Recruiting NCT04206605 Phase 3 Lanadelumab
46 COrticosteroids in acUte uRticAria in emerGency dEpartment Recruiting NCT03545464 Phase 3 Placebo Oral Tablet;Cortancyl Oral Tablet;Levocetirizine Oral Tablet
47 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema Active, not recruiting NCT03485911 Phase 3 BCX7353 capsules;Placebo oral capsule
48 An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema Active, not recruiting NCT03472040 Phase 2, Phase 3 BCX7353
49 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema Active, not recruiting NCT03873116 Phase 3 BCX7353 capsules;BCX7353 capsules;Placebo oral capsule
50 SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects 2 to <12 Years of Age Active, not recruiting NCT04070326 Phase 3 Lanadelumab

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS 71 / NDF-RT 51 :


carbinoxamine
Carbinoxamine maleate
Fluoxymesterone

Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

Anatomical Context for Angioedema

MalaCards organs/tissues related to Angioedema:

40
Skin, Tongue, Endothelial, Thyroid, Brain, Kidney, Heart

Publications for Angioedema

Articles related to Angioedema:

(show top 50) (show all 6338)
# Title Authors PMID Year
1
[Emergency management of acute angioedema]. 61 54
20461661 2010
2
Advances in basic and clinical immunology in 2009. 61 54
20226292 2010
3
Kinins, airway obstruction, and anaphylaxis. 54 61
20519882 2010
4
Increased total and mite-specific immunoglobulin E in patients with aspirin-induced urticaria and angioedema. 54 61
20461968 2010
5
Allergic reaction related to ramipril use: a case report. 61 54
20180980 2010
6
[Angioedema during ACE and DPP-4 inhibition]. 61 54
20196430 2010
7
Acute abdomen due to intestinal angioedema induced by ACE inhibitors: not so rare? 54 61
20163043 2009
8
Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. 54 61
19581503 2009
9
Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. 54 61
19581505 2009
10
Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. 54 61
19178938 2009
11
[Anaesthesic management of vaginal delivery in a parturient with C1 esterase deficiency]. 61 54
19359129 2009
12
Nonallergic hypersensitivity to nonsteroidal antiinflammatory drugs, angiotensin-converting enzyme inhibitors, radiocontrast media, local anesthetics, volume substitutes and medications used in general anesthesia. 54 61
19386216 2009
13
Angioedema after local trauma in a patient on angiotensin-converting enzyme inhibitor therapy. 61 54
18988727 2008
14
Angiotensin converting enzyme inhibitors and delayed onset, recurrent angioedema of the head and neck. 54 61
19023310 2008
15
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. 61 54
18413488 2008
16
[Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate]. 61 54
18096274 2008
17
Endoscopic visualization of angiotensin-converting enzyme inhibitor-induced small bowel angioedema as a cause of relapsing abdominal pain using double-balloon enteroscopy. 54 61
18320317 2008
18
The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. 61 54
18680700 2008
19
[The multiple etiologies of angioedema]. 54 61
18557532 2008
20
New treatments addressing the pathophysiology of hereditary angioedema. 54 61
18410689 2008
21
[Orolingual angioedema as complication after rt-PA in stroke patient treated with ACE inhibitor]. 61 54
18453163 2008
22
Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema. 54 61
18395553 2008
23
Pediatric angioedema. 54 61
18330729 2008
24
Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. 61 54
18295074 2008
25
[Orolingual angioedema secondary to alteplase treatment in cases of stroke]. 54 61
18368687 2008
26
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. 54 61
18084312 2008
27
Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. 54 61
18158172 2008
28
Is dipeptidylpeptidase IV the missing link in angiotensin-converting enzyme inhibitor--induced angioedema? 61 54
18025291 2008
29
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. 61 54
18025295 2008
30
[Angioedema]. 54 61
18004529 2007
31
Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. 61 54
18036423 2007
32
Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. 54 61
17641958 2007
33
Anti-cholesterol antibody levels in hereditary angioedema. 54 61
18205707 2007
34
[ACE-inhibitor induced angioedema]. 54 61
17966084 2007
35
Not all ACE inhibitor related angioedema is always evident: a case which is misdiagnosed as panic attack and speech disorder. 54 61
18047821 2007
36
[Are AT1 receptor antagonists an alternative to ACE inhibitors in angioedema?]. 61 54
18062333 2007
37
[Angioneurotic edema of the head and neck in association with ACE inhibitors]. 54 61
17333046 2007
38
Nonallergic angioedema: role of bradykinin. 54 61
17620062 2007
39
Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. 54 61
17663920 2007
40
[Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers]. 61 54
17540310 2007
41
[Angioedema caused by C1-esterase inhibitor deficiency or ACE inhibitors?]. 61 54
17356860 2007
42
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. 54 61
17291297 2007
43
Olmesartan medoxomil-induced angioedema. 61 54
17341528 2007
44
Anaphylactoid reaction to recombinant tissue plasminogen activator. 61 54
17198333 2007
45
Cutaneous adverse effects of angiotensin-II receptor antagonists. 61 54
17326283 2007
46
Acute upper airway obstruction from acquired angioedema. 61 54
17305664 2007
47
Laboratory testing for C1 inhibitor deficiency: a comparison of two approaches to C1 inhibitor function. 54 61
17270096 2007
48
First case of homozygous C1 inhibitor deficiency. 61 54
17137866 2006
49
Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. 61 54
17285209 2006
50
Angiotensin-converting enzyme inhibitor-associated angioedema. 61 54
17085287 2006

Variations for Angioedema

ClinVar genetic disease variations for Angioedema:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 F12 NM_000505.3(F12):c.983C>G (p.Thr328Arg) SNV Pathogenic 1170 rs118204456 5:176831232-176831232 5:177404231-177404231
2 SERPING1 NM_000062.3(SERPING1):c.1475T>C (p.Met492Thr) SNV Likely pathogenic 427759 rs978962357 11:57382026-57382026 11:57614553-57614553
3 SERPING1 NM_000062.3(SERPING1):c.51+1del Deletion Likely pathogenic 689535 rs1590821401 11:57365792-57365792 11:57598319-57598319
4 SERPING1 NM_000062.3(SERPING1):c.369C>G (p.Cys123Trp) SNV Uncertain significance 689536 rs1465637711 11:57367669-57367669 11:57600196-57600196
5 SERPING1 NM_000062.3(SERPING1):c.1249+5G>C SNV Uncertain significance 689537 rs1590829846 11:57379414-57379414 11:57611941-57611941
6 SYTL2 NM_032943.4(SYTL2):c.890del (p.Ser297fs) Deletion Uncertain significance 375385 rs1057519445 11:85445479-85445479 11:85734436-85734436

Expression for Angioedema

Search GEO for disease gene expression data for Angioedema.

Pathways for Angioedema

Pathways related to Angioedema according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 SERPING1 PLG PLAT KNG1 KLKB1 IL5
2
Show member pathways
12.64 XPNPEP2 MME KNG1 KLKB1 F12 DPP4
3
Show member pathways
12.13 PTGS2 PTGS1 PLG PLAT
4
Show member pathways
12.04 MME DPP4 CPN1 ACE
5
Show member pathways
11.83 SERPING1 PLG PLAT KNG1 KLKB1 F12
6
Show member pathways
11.77 PTGS2 PTGS1 LTC4S
7
Show member pathways
11.53 MME KNG1 BDKRB2 ACE
8 11.39 SERPING1 PLG PLAT KNG1 KLKB1 F12
9 11.31 PLG PLAT KNG1
10 11.04 SERPING1 PLG PLAT KLKB1 F12
11 10.92 PTGS2 PTGS1 LTC4S
12 10.92 PLG PLAT MME ACE
13 10.83 PTGS2 PTGS1
14 10.7 PTGS2 PTGS1
15 10.62 PLG PLAT

GO Terms for Angioedema

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 SERPING1 PLG PLAT KNG1 KLKB1 IL5
2 extracellular region GO:0005576 9.77 XPNPEP2 SERPING1 PLG PLAT KNG1 KLKB1
3 collagen-containing extracellular matrix GO:0062023 9.73 SERPING1 PLG PLAT KNG1 F12 ANGPT1
4 blood microparticle GO:0072562 9.62 SERPING1 PLG KNG1 C1S
5 platelet alpha granule lumen GO:0031093 9.54 SERPING1 PLG KNG1
6 extracellular exosome GO:0070062 9.44 XPNPEP2 SERPING1 PTGS1 PLG PLAT MME

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 PTGS2 PTGS1 KNG1 KLKB1 IL5 HRH1
2 blood coagulation GO:0007596 9.85 SERPING1 PLG PLAT KNG1 KLKB1 F12
3 regulation of complement activation GO:0030449 9.78 SERPING1 CPN1 C1S
4 cellular oxidant detoxification GO:0098869 9.73 PTGS2 PTGS1 LTC4S
5 protein processing GO:0016485 9.69 MME F12 CPN1
6 regulation of blood pressure GO:0008217 9.67 PTGS2 PTGS1 ACE
7 response to glucocorticoid GO:0051384 9.65 PTGS2 HNMT CPN1
8 proteolysis GO:0006508 9.65 XPNPEP2 PLG PLAT MME KLKB1 F12
9 prostaglandin biosynthetic process GO:0001516 9.6 PTGS2 PTGS1
10 lipoxygenase pathway GO:0019372 9.59 PTGS2 LTC4S
11 peptide metabolic process GO:0006518 9.58 MME CPN1
12 amyloid-beta metabolic process GO:0050435 9.58 MME ACE
13 angiotensin maturation GO:0002003 9.57 MME ACE
14 blood coagulation, intrinsic pathway GO:0007597 9.56 SERPING1 KNG1 KLKB1 F12
15 plasminogen activation GO:0031639 9.55 PLAT KLKB1
16 hemostasis GO:0007599 9.55 SERPING1 PLG KNG1 KLKB1 F12
17 cyclooxygenase pathway GO:0019371 9.54 PTGS2 PTGS1
18 regulation of vascular permeability GO:0043114 9.52 HRH1 BDKRB2
19 positive regulation of fibrinolysis GO:0051919 9.5 PLG KLKB1 F12
20 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.46 PTGS2 BDKRB2
21 Factor XII activation GO:0002542 9.43 KLKB1 F12
22 fibrinolysis GO:0042730 9.02 SERPING1 PLG PLAT KLKB1 F12

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.96 XPNPEP2 PLG PLAT MME KLKB1 F12
2 signaling receptor binding GO:0005102 9.83 PLG PLAT KNG1 DPP4 ANGPT1
3 metallopeptidase activity GO:0008237 9.71 XPNPEP2 MME CPN1 ACE
4 endopeptidase activity GO:0004175 9.63 PLG MME ACE
5 serine-type endopeptidase activity GO:0004252 9.63 PLG PLAT KLKB1 F12 DPP4 C1S
6 serine-type peptidase activity GO:0008236 9.43 PLG PLAT KLKB1 F12 DPP4 C1S
7 exopeptidase activity GO:0008238 9.37 MME ACE
8 prostaglandin-endoperoxide synthase activity GO:0004666 9.32 PTGS2 PTGS1
9 peptidase activity GO:0008233 9.32 XPNPEP2 PLG PLAT MME KLKB1 F12

Sources for Angioedema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....